Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Innovative Drug Delivery Systems and Intrac Complete Merger

By Pharmaceutical Processing | December 23, 2004

NEW YORK, NY (December 23, 2004) – Intrac, Inc. and Innovative Drug Delivery Systems (IDDS), Inc. recently announced the two companies have consummated a merger.

The transaction was completed by the merger of a wholly owned subsidiary of Intrac, Inc. with the specialty pharmaceutical company IDDS, a private company, with IDDS remaining as the survivor corporation and a wholly owned operating subsidiary of Intrac.

IDDS also announced that it closed an $18 million private placement of its common stock priced at $3.00 per share. Rodman & Renshaw served as the exclusive placement agent for IDDS.

“I am pleased to reach this milestone in the development of our company,” said Dr. Fred Mermelstein, president and chief executive officer of IDDS. “Institutional investment in our company strengthens our access to broad capital markets and facilitates our clinical development programs as they move towards commercialization.”

On the merger, historical IDDS stockholders received approximately 71.5 percentof Intrac’s outstanding shares, the investors in IDDS’s $18 million private placement received approximately 24 percent of Intrac’s outstanding shares and the existing Intrac equity holders received approximately 4.5 percent of Intrac’s outstanding shares. In addition, IDDS officers and directors will replace Intrac officers and directors and Intrac will implement IDDS’s business plan, the companies said.

IDDS is a specialty pharmaceutical company. The company’s product candidates address the market segment for prescription medications used to treat acute and episodic moderate-to-severe pain associated with breakthrough cancer pain, post operative pain, orthopedic injury, procedural pain, burn pain, and trauma.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE